CDIO
Cardio Diagnostics Holdings, Inc.
There isn't enough reported data to score CDIO yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CDIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
CDIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CDIO PE Valuation
CDIO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CDIO Forward outlook
There aren't enough analyst estimates for CDIO to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CDIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$9.60 | +$53.50 |
| Q2 2024 | -$12.60 | +$45.06 |
| Q1 2024 | -$22.50 | +$25.28 |
| Q4 2023 | -$19.80 | +$25.50 |
| Q3 2023 | -$63.10 | -$61.08 |
| Q2 2023 | -$57.66 | -$55.00 |
| Q1 2023 | -$47.78 | -$46.93 |
| Q4 2022 | -$45.30 | -$45.26 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 126% for CDIO versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CDIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.6K | +26% |
| Q2 2026 | $5.4K | -28% |
| Q1 2026 | $2.7K | +185% |
| Q4 2025 | $3.6K | -21% |
| Q3 2025 | $2.9K | -57% |
| Q2 2025 | $7.5K | -5% |
| Q1 2025 | $940 | -94% |
| Q4 2024 | $4.5K | -15% |
CDIO's revenue is recovering but still below its 2024 peak: $3,590 last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -48194% | +11757 points |
| Q2 2026 | -27951% | -5493 points |
| Q1 2026 | -66598% | +106865 points |
| Q4 2025 | -41160% | -7551 points |
| Q3 2025 | -59951% | -38538 points |
| Q2 2025 | -22458% | -6162 points |
| Q1 2025 | -173464% | -147359 points |
| Q4 2024 | -33608% | -4569 points |
CDIO's operating margin was −48194% last quarter, up 11757 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CDIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CDIO on profitability, with a higher operating margin.
CDIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.5M | +$40.4K |
| Q2 2026 | -$1.3M | +$247.8K |
| Q1 2026 | -$1.6M | -$158.1K |
| Q4 2025 | -$1.4M | +$34.1K |
| Q3 2025 | -$1.6M | -$375.6K |
| Q2 2025 | -$1.6M | -$211.9K |
| Q1 2025 | -$1.4M | -$152.9K |
| Q4 2024 | -$1.4M | +$826.8K |
CDIO has burned cash in almost every quarter: −$6M over the past year, against −$6M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CDIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CDIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +70% | +1.2M shares |
| 3 years | +833% | +2.6M shares |
CDIO has 3M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CDIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CDIO Net Leverage
CDIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CDIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.5 | Neutral |
| Stochastic | 26.3 | Neutral |
CDIO's weekly RSI is 48 (neutral) and its Stochastic is 26 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CDIO PE vs Healthcare Sector
CDIO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CDIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.79 | 4.5% above |
| 20 week MA | $1.83 | 2.2% above |
| 50 week MA | $2.18 | 14% below |
| 100 week MA | $5.53 | 66% below |
| 200 week MA | $21.2 | 91% below |
CDIO has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 91% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CDIO on trend strength, trading above more of its moving averages.
CDIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $294.6 | $32.4 | -89% |
| 2023 | $32.4 | $74.7 | +131% |
| 2024 | $74.7 | $27.8 | -63% |
| 2025 | $27.8 | $3.33 | -88% |
| 2026 YTD | $3.33 | $1.87 | -44% |
CDIO's yearly returns have swung widely, from +131% in 2023 to −89% in 2022. It's down 44% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CDIO on returns for 2026, with the stronger performance.